TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05955222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEK
Description: Participants receiving splints produced with CAD/CAM from PEEK blocks,

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMMA
Description: Participants receiving splints produced with CAD/CAM from PMMA blocks,

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional
Description: Participants receiving splints from vacuum forming system
Study: NCT01124656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone-Azilsartan
Description: Pioglitazone-Azilsartan (30 mg + 20 mg) or (45 mg + 20 mg), tablets, orally, once daily for up to 52 weeks.
Study: NCT02261922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel
Study: NCT01125345

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification
Description: Phacoemulsification with IOL implantation in eyes undergoing bilateral cataract surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification
Description: Phacoemulsification with IOL implantation in eyes undergoing bilateral cataract surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Description: Phacoemulsification with IOL implantation in eyes undergoing bilateral cataract surgery
Study: NCT03470701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mailed Urinalysis Smartphone Kit
Description: Patients who fail to complete albuminuria screening after the initial reminder to do so, will be contacted by phone and offered a mailed smartphone urinalysis kit. Agreeable patients will then receive the mailed kit and instructions to use their smartphone camera to analyze a urine dipstick.
Study: NCT03532568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: 4mm punch skin biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: 4mm punch skin biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: 4mm punch skin biopsy
Study: NCT03969069

Intervention type: DEVICE
Intervention: MAPLe
Description: Additional assessment with MAPLe

Intervention type: DEVICE
Intervention: MAPLe
Description: Additional assessment with MAPLe
Study: NCT03532568

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: narrowband ultraviolet B
Description: narrowband ultraviolet B for CKD-aP patients
Study: NCT00591084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ginsenoside-Rd 10 mg
Description: infusion ginsenoside-Rd 10 mg (group A)once a day and continued for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: infusion placebo (group B)once a day and continued for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ginsenoside-Rd 20mg
Description: infusion of ginsenoside-Rd 20mg (group C) once a day and continued for 14 days
Study: NCT03101098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retroperitoneal liagation of uterine artery
Description: the site of ligation of uterine artery is the area that it originates from the internal iliac artery during TLH

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classical ligation of uterine artery
Description: the site of ligation of uterine artery is the area alongside the cervix
Study: NCT04075526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone iodine
Description: To create the dilute solution, a staff member will draw up 17.5 mL of 10% povidone iodine with a syringe and mix it with 500 mL of normal saline, resulting in a dilution of 0.35% povidone iodine solution for use before wound closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone iodine
Description: To create the dilute solution, a staff member will draw up 17.5 mL of 10% povidone iodine with a syringe and mix it with 500 mL of normal saline, resulting in a dilution of 0.35% povidone iodine solution for use before wound closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin powder
Description: 2 grams of vancomycin powder will be applied to the wound and will be distributed so that approximately 1 gram is administered deep to the fascia and 1 gram superficial to the fascia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin powder
Description: 2 grams of vancomycin powder will be applied to the wound and will be distributed so that approximately 1 gram is administered deep to the fascia and 1 gram superficial to the fascia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: No additional steps in management are required for the control arm of the study besides lavage with 1 L of isotonic sodium chloride solution without antibiotics. No vancomycin powder or dilute povidone iodine lavage would be utilized in this cohort
Study: NCT02717507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacogenomic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study: NCT03501550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: sofosbuvir and velpatasvir fixed dose combination
Study: NCT03982056

Intervention type: OTHER
Intervention: this is an observational study there are no interventions
Description: development of an index to provide appropriate information on a person's ability to float, based on Physiological and anthropometric characteristics

Intervention type: OTHER
Intervention: this is an observational study there are no interventions
Description: development of an index to provide appropriate information on a person's ability to float, based on Physiological and anthropometric characteristics
Study: NCT05028686

Intervention type: OTHER
Intervention: No intervention
Description: Observational cohort
Study: NCT00900809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neukoplast™ (NK-92)
Description: The Neukoplast™ (NK-92) cells will be administered intravenously over 60 minutes. The starting dose of Neukoplast™ (NK-92) cells will be 1 x 10e9 ZRx-101 cells/m2 (The 3 dose levels are: 1 x 10e9 cells/m2, 3 x 10e9 cells/m2 and 5 x 10e9 cells/m2). The second infusion will only be administered after 24 hours if no unacceptable or dose limiting toxicities side effects due to the infusion of Neukoplast™ were encountered after the first infusion.
Study: NCT03311009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 cohort 1
Description: GLPG1972 dose 1 provided as oral tablets q.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 cohort 2
Description: GLPG1972 dose 2 provided as oral tablets q.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 cohort 3
Description: GLPG1972 dose 3 provided as oral tablets q.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo provided as oral tablets q.d.
Study: NCT02387814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered Orally
Study: NCT04503798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Goal Management Training
Description: Pre-recorded videos and games combine psycho-education, targeted skills training, and mindfulness practice to teach a system where participants can take control of their attention and cognitive faculties.
Study: NCT02002156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
Description: This group will receive BCG at birth and all routine vaccinations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
Description: This group will receive BCG at three months old and all routine vaccinations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
Description: This group will receive no BCG but will receive all routine vaccinations.
Study: NCT00833781

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-transfected autologous dendritic cells
Description: Injections will be administered intradermally at weeks 0, 2, 6 and 10.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: autologous dendritic cells with no mRNA transfection
Description: Injections will be administered intradermally at weeks 0, 2, 6 and 10.
Study: NCT05464732

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vivity IOL
Description: The Vivity IOL will be implanted bilaterally in all subjects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivity IOL
Description: The Vivity IOL will be implanted bilaterally in all subjects.
Study: NCT02307474

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: 3 fractions of 16 Gy per fraction to a total dose of 48 Gy on non-consecutive day within a 10 day time span

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO starting at 800mg to be systematically altered following drug related toxicities.
Study: NCT01847313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Daily administration of liraglutide for 6 months
Study: NCT02459613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-Annexin V-128 SPECT
Study: NCT00229541

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Counselling and 3-week medical in-patient rehabilitation
Description: Counselling and 3-week medical in-patient rehabilitation in IG
Study: NCT03253978

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotatic Radiotherapy
Description: SABR to prostate / seminal nodes

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotatic Radiotherapy
Description: SABR to prostate / seminal nodes
Study: NCT04034030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Each patient will receive a 10 minute treatment of one time stimulation of the Epileptogenic Cortical Area (ECA). The TRPMS cap will be worn over the previously fixed scalp EEG electrodes. The procedure during this treatment session will consist of positioning a device microstimulator component centered on an area of focal epileptiform discharges (identified with EEG electrode placement) with the patient relaxing in a chair.~The stimulus parameters used will be 120 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 10 min. . The investigators will measure the subject for adequate placement of the device prior to stimulation. Once the placement of the device is confirmed, the study technician administrating the treatment will turn on the device using the app downloaded on an electronic device connected by Bluetooth to the device.
Study: NCT03863275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional apparatus
Description: The EMG activity will be recorded during different shots: T0. The activity of the muscles of the mastication in the position of clinical rest for a minute, in maximum intercuspidation. (It will be measured with a dynamometer to standardize the force), and with the use of the equipment. T1 The patient's citation is scheduled six months after the use of myofunctional device Sn1 and the test will be performed again measuring electrical activity of right and left masseter and right and left temporal muscle at clinical rest for one minute, in maximum intercuspation, and with the use of the equipment To avoid the effects of fatigue, a rest period of at least 5 minutes between each of the recordings will be allowed

Intervention type: OTHER
Group type: OTHER
Intervention: Diagnosis and observation
Description: Six months of observation in the control group: patients group the efforts are controlled. to obtain models and have an observation of the molar classification, and to verify if the terms of the inclusion in the study are taken into account, once it is confirmed that the activity is observed in the muscular activity of the chewing muscles, in two stages , at the beginning of the session and six months later. .
Study: NCT00877682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Under general anesthetic using ultrasonic guidance, freezing (cryoablation) portion of prostate.
Study: NCT00563303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: 200mg/jour (solution of 48mL), Day 1 to Day 4 100mg/jour (solution of 48mL), Day 5 50mg/jour (solution of 48mL), Day 6

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: 48mL from Day 1 to Day 6
Study: NCT03323632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyndMove
Description: During a MyndMove therapy session, the patient is instructed to attempt to execute a task voluntarily. As the patient is attempting to perform the designated task, specific muscles in the arm are stimulated to generate contractions that produce the desired movement. After a brief interval of the patient attempting to initiate a movement the therapist activates the MyndMove stimulation protocol, which generates bursts of short electrical pulses, using surface electrodes, to produce muscle contractions enabling the patient to complete the desired/instructed task. Proper sequencing of the muscle contractions as per the MyndMove protocols are tailored to achieve a wide range of reaching and grasping functions. The technique stimulates non-damaged pathways of the central nervous system.
Study: NCT00864942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine and lenalidomide
Description: Lenalidomide is given daily orally for one week followed by bendamustine HCL 90 mg/m2 IV over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-NHL
Description: Bendamustine HCL 90 mg/m2 given intravenously over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLR-CLL
Description: Lenalidomide is given orally for 7 days followed by rituximab 375 mg/m2 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLR-NHL
Description: Rituximab 375 mg/m2 is given on day 1 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
Study: NCT03803722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyestil Protection® unidose
Description: to demonstrate the non-inferiority of Eyestil Protection® in terms of performance and safety, when compared to Vismed® in treatment of dry eye disease.
Study: NCT01301131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: 80 ml of fermented dairy product containing L. casei shirota via nasogastric tube once daily and 80 ml of fermented dairy product containing L. casei shirota oral rinse once daily

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: control
Description: usual oral care
Study: NCT01040013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Description: Laparoscopic Left-Colectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: left colectomy by laparotomy
Description: PatientS will be operated by laparotomy
Study: NCT02609737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT Imaging

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-JR11

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-JR11
Study: NCT01806597

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: secukinumab 150 mg
Description: Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consiseds of one secukinumab 150 mg s.c. injection plus one placebo secukinumab s.c. injection and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also received two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg
Description: Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consisted of two secukinumab 150 mg s.c. injections and took ke place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also receives two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo were provided in 1 mL pre-filled syringes. Each dosing consisted of two s.c. injections and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then at Week 8 and at Week 12. At Week 16, ppIGA responders continued on placebo with dosing at Weeks 16, 17, 18, 19 and 20, then once every four weeks from Week 24 until Week 76 inclusive. At Week 80, ppIGA responders ended their participation in the study while ppIGA non-responders were re-randomized, to receive 150 mg or 300 mg secukinumab once every four weeks starting at Week 80 until Week 128 inclusive. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
Study: NCT02958540

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SynGEM
Description: Prime / boost vaccination in each group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SynGEM
Description: Prime / boost vaccination in each group

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: prime /boost vaccination
Study: NCT01017029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil + Everolimus
Study: NCT00139386

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Description: Candesartan Cilexetil (4-12 mg per day)
Study: NCT01938300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study: NCT02419859

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PaQ® Insulin Delivery Device
Description: PaQ is a 3 day insulin delivery device which delivers U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin, Asp(B28)-
Description: a fast-acting analog of human insulin
Study: NCT00879554

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVX-045
Description: Weekly, intravenous dose
Study: NCT04290078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kaia Back Pain Study App
Description: Kaia Back Pain is an integrated solution for self-management of low-back pain that digitizes multidisciplinary rehabilitation into a smartphone application.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in the control arm will be provided with online links to educational materials about home exercises and pain management and asked to continue their usual care. On-line resources will include links to Web MD, the National Library of Medicine (Medline), and OnHealth
Study: NCT04967716

Intervention type: OTHER
Intervention: basic information
Description: Demographic data registration, medical history inquiry, physical examination; electromyography, nerve conduction velocity examination; CMT nerve function score;

Intervention type: OTHER
Intervention: venous blood test
Description: The specific method is as follows: 12ml of peripheral blood is drawn from the peripheral vein, and EDTA is used for anticoagulation. No fasting is required before blood draw, and there is no time limit. Part of the specimens submitted for inspection are sent to a qualified genetic testing company for examination, and the fees are charged in accordance with the corresponding charging standards set by the hospital. The remaining part of the sample will be stored or accumulated for a period of time, and the DNA will be extracted and stored in the sample library.
Study: NCT00698178

Intervention type: OTHER
Intervention: Anthropometric measurements
Description: All patients undergo anthropometric measurements to record body weight, body height and waist circumference on the day of enrollment

Intervention type: OTHER
Intervention: Anthropometric measurements
Description: All patients undergo anthropometric measurements to record body weight, body height and waist circumference on the day of enrollment